Is there a treatment for sepsis other than antibiotics?  by Paul, M.




Bacterial sepsis is a complex cascade of events that I cannot
claim to begin to understand. Clearly, bacteria are involved,
and they have many different toxic mechanisms, including the
production of endotoxins, exotoxins, cytotoxins, and proco-
agulants. The host responds at the local and systemic levels
with changes in gene regulation, recruitment of white blood
cells, changes in the coagulation cascade, modiﬁcation of sig-
nalling pathways, production of cytotoxins, and probably
much more. Haemodynamic and metabolic changes result in,
and affect, end-organ function. However, regardless of the
pathways, in the current theme section we ask how we can
treat sepsis. Early appropriate antibiotic treatment and hae-
modynamic resuscitation are indisputably the most important
components of treatment. In this theme section, we go
beyond the basics of current treatment to explore other
modalities.
Cohen convincingly explains why antibiotics are not
enough. He presents steps in the sepsis cascade where we
should perhaps intervene, and the various modalities that
have been designed for this. As theory is much more exten-
sive than the drugs we currently have in our armamentarium
for the treatment of sepsis, the question that arises is: does
the probem lie in ﬁnding the right drug or knowing how to
test it?
Minneci et al. present an updated systematic review and
meta-analysis concerning the effects of corticosteroids on
survival in sepsis. Their compilation of all trials to date and
their analysis of these leads to some understanding of what
underlies the effect of steroids in sepsis. They demonstrate
that corticosteroids, started at c. 300 mg/day of hydrocorti-
sone equivalents and reduced stepwise over c. 6 days, signiﬁ-
cantly improves overall survival. This effect was seen in
severe sepsis, when mortality in the control group was
above 25%, which corresponds to an APACHE II score of
above 16.
Kopterides and Falagas summarize studies that have
assessed statins in the context of sepsis. Statins represent
but one of several non-antibiotic medications that have been
claimed to improve survival in cases of sepsis. These claims
originate from observational studies that, as Leibovici
describes, examine chance ﬁndings and are prone to ‘healthy
user’ bias. Although our ability to adjust for the healthy user
bias when comparing patients treated or untreated with a
chronic medication is a priori questionable, the studies assess-
ing statins were particularly plagued by poor methodology
and adjustment methods. It is therefore of some surprise
that randomized controlled trials assessing statins for the
treatment of sepsis are currently ongoing.
Houston and Cuthbertson present the evidence and con-
troversies surrounding the use of activated protein C for the
treatment of sepsis. Thirty-ﬁve years after the discovery of
the molecule and after more than 10 years of clinical trials,
we remain in a position with more questions than answers.
An answer with some certainty exists only for the question
of who should not be given activated protein C.
We did not review the topics of glucose control and
nutrition in sepsis, which are of great relevance and are open
to debate in the management of sepsis. We did not review
many speciﬁc immune modulators that have been assessed
in clinical trials. Ultimately, we can summarize that we have
little to offer patients with severe sepsis other than adequate
antibiotics and full haemodynamic support. A better under-
standing of the full implications of the sepsis cascade might
yet yield more effective and individualized interventions.
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